MYOMO, INC.
No enriched coverage for $MYO in the last 7 days.
No SEC Form 4 filings for $MYO in the last 30 days.
See all $MYO insider activity →Myomo (MYO) said MyoConnect referrals rose to 17% of Q2 pipeline additions from 11% in Q1. Of 739 patients added, about 122 came from referrals. Gross margin increased to 72.1% from 62.7%. Q2 net loss was $4.0M ($0.09/share). Q3 revenue guidance is $11.5M to $12.0M, and full-year revenue outlook raised to $45M to $47M.
Biotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.
MYOMO, INC. (MYO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 myo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Myomo Reports Second Quarter 2026 Financial and Operating Results Revenue of $11.7 million, increased 21% year over year Four success pillars driving higher revenue growth and operating leverage Raising full year revenue guida
Recent MYO coverage spans market movers, earnings and insider activity.
Raised guidance and improved gross margin suggest improving unit economics and demand quality, supporting a near-term re-rate versus prior expectations.
Raised revenue guidance indicates improving demand and unit economics, supporting a constructive near-term growth outlook.
Guidance raise plus operating leverage improvement (expenses roughly flat, gross margin up) supports a near-term re-rating, but losses and cash burn remain key watch items.
Share-authorization and equity-plan share increases can affect dilution expectations and near-term sentiment, but no earnings or guidance change is disclosed.
The move appears sentiment/positioning-driven rather than catalyst-driven; guidance reiteration may be insufficient to sustain a trend.
alphai scores every news story that mentions MYO with an AI model for sentiment and relevance, and aggregates insider trades from MYOMO, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Myomo (MYO) said MyoConnect referrals rose to 17% of Q2 pipeline additions from 11% in Q1. Of 739 patients added, about 122 came from referrals. Gross margin increased to 72.1% from 62.7%. Q2 net loss was $4.0M ($0.09/share). Q3 revenue guidance is $11.5M to $12.0M, and full-year revenue outlook raised to $45M to $47M.
6 min readBiotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.
3 min readMYOMO, INC. (MYO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 myo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Myomo Reports Second Quarter 2026 Financial and Operating Results Revenue of $11.7 million, increased 21% year over year Four success pillars driving higher revenue growth and operating leverage Raising full year revenue guida
6 min readMYOMO, INC. (MYO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001369290 --12-31 false 0001369290 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J
3 min readRegentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.
6 min readBiotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.
7 min readKIRK THOMAS F purchased 40,002 shares of MYOMO, INC. (MYO) at $1.27 on 2026-06-05.
1 min readKIRK THOMAS F purchased 25,000 shares of MYOMO, INC. (MYO) at $0.99 on 2026-05-28.
2 min readRosalind Advisors, Inc. significantly increased its stake in Myomo Inc. by adding over 3.8 million shares on December 31, 2025. This move boosts Rosalind Advisors' total holding to over 7.6 million shares and reflects its confidence in the medical robotics company's long-term potential, despite Myomo Inc.'s current financial challenges and status as a possible value trap. The investment firm, known for value investing, now holds 9.90% of its Myomo Inc. position, impacting its overall portfolio by 1.18%.
2 min readMyomo Inc. MYO shares tumbled 42.05% in pre-market trading to $1.02 despite reporting second-quarter revenue that exceeded expectations, as investors focused on the medical robotics company's significantly reduced full-year guidance and widening losses. Check out the current price of MYO stock here.
3 min read
